CagriSema vs L-Carnitine
A side-by-side research comparison of CagriSema and L-Carnitine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | L-Carnitine |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | L-Carnitine Injectable |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Supplement / Compounded |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine shuttle, enabling beta-oxidation for ATP production. Also reduces oxidative stress and supports cardiac function. |
| Molecular weight | Combination product | 161.20 Da |
| Half-life | 7 days (both components) | ~2-3 hours (IM) |
| Bioavailability | High (SubQ) | ~100% injectable; ~14-18% oral |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 500-2000 mg |
| Frequency | Once weekly | 2-5x per week |
| Route | Subcutaneous | Intramuscular or IV injection |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
L-Carnitine reported benefits
- Enhanced fat oxidation
- Improved energy
- Exercise performance
- Cardiac health
- Recovery support
- Mitochondrial function
Related comparisons
Research and educational reference only. Not medical advice.